# China NMPA Drug Inspection - Jiangxi Sanyuan Pharmaceutical Co., Ltd. - Rheumatism Pain Medicated Wine

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/jiangxi-sanyuan-pharmaceutical-co-ltd/a04acfb0-1539-4a02-8cef-d436b0b27a1e/
Source feed: China

> China NMPA drug inspection for Jiangxi Sanyuan Pharmaceutical Co., Ltd. published July 27, 2017. Drug: Rheumatism Pain Medicated Wine. The Hubei Province Drug Quality Announcement, issued on July 27, 2017, reported the findings from drug quality inspectio

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Hubei Province Drug Quality Bulletin (Issue 2, 2017)
- Company Name: Jiangxi Sanyuan Pharmaceutical Co., Ltd.
- Publication Date: 2017-07-27
- Drug Name: Rheumatism Pain Medicated Wine
- Inspection Finding: Properties
- Action Taken: The food and drug administration departments of each city (prefecture) shall investigate and handle the matter in accordance with the provisions of the "Drug Administration Law of the People's Republic of China", and report the results and relevant information to the provincial bureau in a timely manner.
- Summary: The Hubei Province Drug Quality Announcement, issued on July 27, 2017, reported the findings from drug quality inspections conducted across the province during the second quarter of 2017. These inspections involved drug production, operation, and use units, revealing 30 batches of drugs that did not meet established quality standards. Key violations included quality control deficiencies such as improper dissolution (e.g., Norfloxacin Capsules from Chengdu Jinhua Pharmaceutical Co., Ltd.), excessive related substances (e.g., Vitamin K1 Injection from Wuhu Kangqi Pharmaceutical Co., Ltd. and Shandong Yikang Pharmaceutical Co., Ltd.), and issues with pH value, weight variation, moisture content, or product identification. Notably, counterfeit drugs like Osteoarthritis Capsules and Compound Cough and Asthma Relief Capsules were found to contain undeclared active ingredients, specifically Prednisolone Acetate. Several traditional Chinese medicine preparations and raw materials also exhibited non-compliance in their properties or purity. For some non-compliant batches, manufacturers, including Qingdao Huanghai Pharmaceutical Co., Ltd., disputed production. Operating under the 

Company: https://www.globalkeysolutions.net/companies/jiangxi-sanyuan-pharmaceutical-co-ltd/f10390ac-d0ec-41ee-91f0-6f483ef94185/